Chances are, you’ve never walked into a store and bought something with the ASML logo on it but almost every smartphone, tablet, or electric vehicle in your life probably wouldn’t exist without ASML’s technology humming away in the background.
This Dutch powerhouse doesn’t make chips, it makes the machines that make the chips.
» Read more about: Forget Nvidia, This Under-the-Radar Chip Stock Might Have More Upside »
Warren Buffett isn’t a market timer. Never has been, never will be. Instead, he’s a value hawk, someone who circles the skies looking for bargains and only swoops in when the numbers justify it. In his 1994 letter to shareholders, Buffett put it plainly: “We try to price, rather than time, purchases.”
That simple principle explains why he often appears to be doing… well,
SoFi’s rise over the past few years has been stunning. SoFi’s stock has surged over 3x over the past 3 years, handily outpacing blue-chip tech names, even those riding the artificial intelligence wave. But that eye-popping run might be both a blessing and a curse.
Investors are now wondering whether SoFi keep up the pace?
» Read more about: Is SoFi Still a Once-in-a-Generation Fintech Opportunity »
The stock market has a way of turning heroes into villains overnight, and Block is a perfect case study. Just a few years ago, it was one of the hottest names on Wall Street, riding high on the wave of digital adoption.
Fast forward to today, and the stock is trading nearly 80% below its all-time highs.
» Read more about: Jack’s Fintech Giant Just Quadrupled Profits »
If you’re the kind of investor who wants steady income, especially the kind that drops into your account every month like clockwork, the JPMorgan Equity Premium Income ETF (JEPI) is tough to ignore.
The headline number is eye-catching, an 8.6% trailing yield, paid monthly. That’s not just high, it’s more than four times the yield of the S&P 500 and well above what most high-grade corporate bonds are paying right now.
Merck has long been a pillar of stability in the pharmaceutical world, thanks in large part to the staggering success of its cancer drug Keytruda. But behind that success lies a quietly growing concern of what happens when the patents expire?
In a move that could reshape its future, Merck just announced a $10 billion acquisition of Verona Pharma.
» Read more about: 4% Dividend + 12x Earnings = Blockbuster in the Making »
Novo Nordisk, the pharmaceutical giant behind weight-loss blockbusters Ozempic and Wegovy, just let a key patent on semaglutide lapse in Canada because it forgot to pay a routine maintenance fee, the pharmaceutical equivalent of forgetting to renew your car registration.
As a result, generic versions of semaglutide, the active ingredient in both drugs,
» Read more about: How a $300 Mistake Opened a $1 Billion Market »
BigBear.ai (NYSE: BBAI) has all the buzzwords that investors love these days AI, defense, government contracts but does that make it a great investment?
Some traders are hoping the stock will 3x but as any seasoned investor knows, hope isn’t a strategy. If you’re wondering what it would actually take to get there,
SoundHound AI isn’t chasing the same crowded lane as other AI giants. Instead of building general-purpose AI models or chasing flashy headlines, it has carved out a very specific, and potentially lucrative, niche, voice AI.
At its core, SoundHound builds sophisticated voice recognition and natural language processing software that enables real-time, conversational interactions between humans and machines.
» Read more about: Could This $5 Billion Minnow Be the Next Big AI Buyout Target? »
In the world of rideshare investing, Uber tends to get all the attention. And with autonomous driving hype swirling around Tesla, it’s easy to overlook the other major U.S. player in the space. But if you’re willing to dig deeper, Lyft (NASDAQ: LYFT) might just be one of the market’s most overlooked opportunities.
Lyft targets the $59.2B U.S.
» Read more about: Why Lyft Might Be The Highest Potential Stock Now »
